SUPN · Supernus Pharmaceuticals, Inc.
Market Cap
$2.56B
Shares
58.13M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-08-03 | 2026-09-30 | |
| 8-K | 2026-08-03 | — | |
| 8-K | 2026-08-03 | — | |
| 10-Q | 2026-08-03 | 2026-06-30 | |
| 8-K | 2026-08-03 | — | |
| 8-K | 2026-08-03 | 2026-08-01 | |
| 8-K | 2026-07-22 | — | |
| 8-K | 2026-06-18 | — | |
| Investor Event Transcript | 2026-06-03 | 2026-06-30 | |
| 8-K | 2026-05-20 | 2026-05-17 | |
| 8-K | 2026-05-05 | — | |
| 10-Q | 2026-05-05 | 2026-03-31 | |
| DEF 14A | 2026-04-30 | 2026-06-18 | |
| 8-K | 2026-04-22 | — | |
| 8-K | 2026-04-07 | 2026-04-01 | |
| Investor Event Transcript | 2026-03-31 | — | |
| 10-K | 2026-03-02 | 2025-12-31 | |
| 8-K | 2026-02-24 | — | |
| 8-K | 2026-02-24 | — | |
| 8-K | 2026-02-12 | — | |
| 8-K | 2026-01-28 | — | |
| 10-Q | 2025-11-06 | 2025-09-30 | |
| 8-K | 2025-11-04 | — | |
| 8-K | 2025-10-21 | — | |
| 8-K/A | 2025-10-16 | 2025-07-31 | |
| 8-K | 2025-08-05 | — | |
| 10-Q | 2025-08-05 | 2025-06-30 | |
| 8-K | 2025-08-04 | 2025-06-16 | |
| 8-K | 2025-07-31 | 2025-07-30 | |
| 8-K | 2025-07-22 | — | |
| 8-K | 2025-06-17 | 2025-06-16 | |
| 8-K | 2025-06-16 | 2025-06-13 | |
| 8-K | 2025-05-28 | 2025-05-22 | |
| 10-Q | 2025-05-06 | 2025-03-31 | |
| 8-K | 2025-05-06 | — | |
| DEF 14A | 2025-04-30 | 2025-06-16 | |
| 8-K | 2025-04-23 | — | |
| 8-K | 2025-02-25 | — | |
| 10-K | 2025-02-25 | 2024-12-31 | |
| 8-K | 2025-02-24 | — | |
| 8-K | 2025-02-18 | — | |
| 8-K | 2025-02-11 | — | |
| 8-K | 2025-02-04 | — | |
| 8-K | 2025-01-27 | — | |
| 8-K | 2024-12-20 | 2024-12-19 | |
| 8-K | 2024-11-04 | — | |
| 10-Q | 2024-11-04 | 2024-09-30 | |
| 8-K | 2024-10-30 | — | |
| 8-K | 2024-10-21 | — | |
| 8-K | 2024-10-17 | — |
Showing 1–50 of 177 filings
Key facts
CIK
1356576
CUSIP
868459108
13F (30d)
229 filings
226 filers
Visit website
Investor relations